[
  {
    "ts": null,
    "headline": "Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value",
    "summary": "Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.",
    "url": "https://finnhub.io/api/news?id=55d1529df95faa211f30c69c3af5c9bc27914aaccba3736ed4c24b15134a2681",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734134056,
      "headline": "Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value",
      "id": 131977467,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.",
      "url": "https://finnhub.io/api/news?id=55d1529df95faa211f30c69c3af5c9bc27914aaccba3736ed4c24b15134a2681"
    }
  },
  {
    "ts": null,
    "headline": "This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed For A Monster Year In 2025?",
    "summary": "Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial for its Parkinson's medication. Biotech firms live and die on the success of the medications they develop and clinical testing ...",
    "url": "https://finnhub.io/api/news?id=8a4cc0408f3d0f59d948c178406a5979718e93aa9c77679a56e4b0311060de65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734116415,
      "headline": "This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed For A Monster Year In 2025?",
      "id": 131972713,
      "image": "https://media.zenfs.com/en/benzinga_79/ae153d79786c191a5903d3be7c7b6020",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial for its Parkinson's medication. Biotech firms live and die on the success of the medications they develop and clinical testing ...",
      "url": "https://finnhub.io/api/news?id=8a4cc0408f3d0f59d948c178406a5979718e93aa9c77679a56e4b0311060de65"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Friday when compared to competitors despite daily gains",
    "summary": "AbbVie Inc. stock underperforms Friday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=5983732e9d05ae7a9e45573f7e0de801f0a1441a453c6367b0a47fe2b73add08",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734107640,
      "headline": "AbbVie Inc. stock underperforms Friday when compared to competitors despite daily gains",
      "id": 132064991,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Friday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=5983732e9d05ae7a9e45573f7e0de801f0a1441a453c6367b0a47fe2b73add08"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline",
    "summary": "AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to hel",
    "url": "https://finnhub.io/api/news?id=f205e3b376db7e7db088fe509513d5c83ebf9dc287978877ed82e586c35c73a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734099300,
      "headline": "AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline",
      "id": 131970042,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to hel",
      "url": "https://finnhub.io/api/news?id=f205e3b376db7e7db088fe509513d5c83ebf9dc287978877ed82e586c35c73a4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to acquire Roche spinout Nimble in immune drug deal",
    "summary": "The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi.",
    "url": "https://finnhub.io/api/news?id=b8195b63991b3ba43f51a86c7042485c26697351a1b0bf909b40b0d3bbe50259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734087600,
      "headline": "AbbVie to acquire Roche spinout Nimble in immune drug deal",
      "id": 131969105,
      "image": "https://imgproxy.divecdn.com/iPn44wUA8rCYGL9pk-fMf4CsdiwOOluRcP9xfzsfEjg/g:nowe:0:158/c:2047:1157/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9BYmJWaWVfVVNfSGVhZHF1YXJ0ZXJzLmpwZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi.",
      "url": "https://finnhub.io/api/news?id=b8195b63991b3ba43f51a86c7042485c26697351a1b0bf909b40b0d3bbe50259"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Buying Nimble Therapeutics for $200 Million to Boost Immunology Pipeline",
    "summary": "By Colin Kellaher AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive...",
    "url": "https://finnhub.io/api/news?id=59f2b315cf5ec0def53d79e0a7959ead305a0fd33a1fd0ac147e7fcc823ca8a8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734083715,
      "headline": "AbbVie Buying Nimble Therapeutics for $200 Million to Boost Immunology Pipeline",
      "id": 131966336,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive...",
      "url": "https://finnhub.io/api/news?id=59f2b315cf5ec0def53d79e0a7959ead305a0fd33a1fd0ac147e7fcc823ca8a8"
    }
  },
  {
    "ts": null,
    "headline": "American Century Growth Fund Q3 2024 Commentary",
    "summary": "The broad U.S. stock market posted solid gains that saw a reversal of first-half  trends. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=4ff36e88373737720c7fd00f3c4e9dd534f9310a1128306049df92336f433aad",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734083100,
      "headline": "American Century Growth Fund Q3 2024 Commentary",
      "id": 131966292,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400960132/image_1400960132.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The broad U.S. stock market posted solid gains that saw a reversal of first-half  trends. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=4ff36e88373737720c7fd00f3c4e9dd534f9310a1128306049df92336f433aad"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline",
    "summary": "AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline",
    "url": "https://finnhub.io/api/news?id=3b5829092af01c9a99bdf374a62cde273668d5b0df47c0803e33d47aa7145f51",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734082740,
      "headline": "AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline",
      "id": 132064992,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline",
      "url": "https://finnhub.io/api/news?id=3b5829092af01c9a99bdf374a62cde273668d5b0df47c0803e33d47aa7145f51"
    }
  },
  {
    "ts": null,
    "headline": "Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends",
    "summary": "Top Dividend Kings for long-term investing in 2024, including high-yielders and top-gain potentials across various sectors. Click here for a detailed analysis.",
    "url": "https://finnhub.io/api/news?id=c7d9d5354e7b0187802c8c8bf9303b5c3a239351da8713caece8c7a88998af6c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734064869,
      "headline": "Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends",
      "id": 131962234,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/463886019/image_463886019.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Top Dividend Kings for long-term investing in 2024, including high-yielders and top-gain potentials across various sectors. Click here for a detailed analysis.",
      "url": "https://finnhub.io/api/news?id=c7d9d5354e7b0187802c8c8bf9303b5c3a239351da8713caece8c7a88998af6c"
    }
  }
]